Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease

JAMA - Journal of the American Medical Association

Volumn 317, Issue 9, 2017, Pages 937-946

  Khera, Amit V ^a,b   Won, Hong Hee ^c   Peloso, Gina M ^a,d   O'Dushlaine, Colm ^e   Liu, Dajiang ^f   Stitziel, Nathan O ^g   Natarajan, Pradeep ^a,b   Nomura, Akihiro ^a,b   Emdin, Connor A ^a,b   Gupta, Namrata ^a   Borecki, Ingrid B ^e   Asselta, Rosanna ^h,i   Duga, Stefano ^h,i   Merlini, Piera Angelica ^j   Correa, Adolfo ^k   Kessler, Thorsten ^e,l   Wilson, James G ^k   Bown, Matthew J ⁿ   Hall, Alistair S ^o   Braund, Peter S ⁿ   Carey, David J ^p   Murray, Michael F ^p   Kirchner, H Lester ^p   Leader, Joseph B ^p   Lavage, Daniel R ^p   Manus, J Neil ^p   Hartzel, Dustin N ^p   Samani, Nilesh J ⁿ   Schunkert, Heribert ^m   Marrugat, Jaume ^q   Elosua, Roberto ^q   McPherson, Ruth ^r   Farrall, Martin ^s,t   Watkin, Hugh ^s,t   Lander, Eric S ^a   Rader, Daniel J ^u   Danesh, John ^v,w,x   Ardissino, Diego ^y,z   Gabriel, Stacey ^a   Willer, Cristen ^aa   Abecasis, Gonçalo R ^ab   Saleheen, Danish ^x   Dewey, Frederick E ^e   Kathiresan, Sekar ^a,b   more..

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Sungkyunkwan University   (South Korea)

^d BOSTON UNIVERSITY   (United States)

^e AB)   (United States)

^f PENN STATE COLLEGE OF MEDICINE   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h HUMANITAS UNIVERSITY   (Italy)

ⁱ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^j OSPEDALE NIGUARDA CA GRANDA   (Italy)

^k UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^l Munich Heart Alliance   (Germany)

^m TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁿ UNIVERSITY OF LEICESTER   (United Kingdom)

^o UNIVERSITY OF LEEDS   (United Kingdom)

^p GEISINGER HEALTH SYSTEM   (United States)

^q HOSPITAL DEL MAR   (Spain)

^r UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^s UNIVERSITY OF OXFORD   (United Kingdom)

^t UNIVERSITY OF OXFORD   (United Kingdom)

^u UNIVERSITY OF PENNSYLVANIA   (United States)

^v UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^w WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^x UNIVERSITY OF PENNSYLVANIA   (United States)

^y UNIVERSITY HOSPITAL OF PARMA   (Italy)

^z Associazione per lo Studio della Trombosi in Cardiologia   (Italy)

^aa UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^ab UNIVERSITY OF MICHIGAN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN LIPASE; TRIACYLGLYCEROL; LIPOPROTEIN; LPL PROTEIN, HUMAN;

ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; LOSS OF FUNCTION MUTATION; LPL GENE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MISSENSE MUTATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; GENETICS; MUTATION; ODDS RATIO; ONSET AGE;

ADULT; AGE OF ONSET; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; LIPOPROTEIN LIPASE; LIPOPROTEINS; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; TRIGLYCERIDES;

EID: 85015922086     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.0972     Document Type: Article

References (37)

1. Eckel RH. Lipoprotein lipase: A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med. 1989;320(16):1060-1068.
2. Brunzell JD, Deeb SS. Familial lipoprotein lipase deficiency, apo CII deficiency and hepatic lipase deficiency. In: Scriver CR, Beaudet AI, SlyWS, Valle D, eds. TheMetabolic and Molecular Basis of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2000:2789-2816.
3. Nordestgaard BG, Stender S, Kjeldsen K. Reduced atherogenesis in cholesterol-fed diabetic rabbits: Giant lipoproteins do not enter the arterial wall. Arteriosclerosis. 1988;8(4):421-428.
4. Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118(4):547-563.
5. Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjaerg-Hansen A. Heterozygous lipoprotein lipase deficiency: Frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation. 1997;96(6):1737-1744.
6. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation. 2003;107(8):1117-1122.
7. Do R, Stitziel NO,Won HH, et al; NHLBI Exome Sequencing Project. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015;518(7537):102-106.
8. Taylor HA Jr, Wilson JG, Jones DW, et al. Toward resolution of cardiovascular health disparities in African Americans: Design and methods of the Jackson Heart Study. Ethn Dis. 2005;15(4)(suppl 6):S6-S4, 17.
9. Crosby J, Peloso GM, Auer PL, et al; TG and HDLWorking Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22-31.
10. McPherson R, Pertsemlidis A, Kavaslar N, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316(5830): 1488-1491.
11. Clarke R, Peden JF, Hopewell JC, et al; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518-2528.
12. Saleheen D, Zaidi M, Rasheed A, et al. The Pakistan Risk of Myocardial Infarction Study: A resource for the study of genetic, lifestyle and other determinants ofmyocardial infarction in South Asia. Eur J Epidemiol. 2009;24(6):329-338.
13. Sentí M, Tomás M, Marrugat J, Elosua R; REGICOR Investigators. Paraoxonase1-192 polymorphism modulates the nonfatalmyocardial infarction risk associated with decreased HDLs. Arterioscler Thromb Vasc Biol. 2001;21(3):415-420.
14. Samani NJ, Erdmann J, Hall AS, et al;WTCCC and the Cardiogenics Consortium. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357(5):443-453.
15. Stitziel NO, Stirrups KE, Masca NG, et al; Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med. 2016;374(12):1134-1144.
16. Dewey FE, Gusarova V, O'Dushlaine C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374 (12):1123-1133.
17. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospectivemeta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278.
18. Stitziel NO,Won HH, Morrison AC, et al; Myocardial Infarction Genetics Consortium Investigators. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014;371(22):2072-2082.
19. Benn M,Watts GF, Tybjærg-Hansen A, Nordestgaard BG. Mutations causative of familial hypercholesterolaemia: Screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J. 2016;37(17):1384-1394.
20. Jørgensen AB, Frikke-Schmidt R,West AS, Grande P, Nordestgaard BG, Tybjærg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors formyocardial infarction. Eur Heart J. 2013;34(24): 1826-1833.
21. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297-1303.
22. Landrum MJ, Lee JM, Riley GR, et al. ClinVar: Public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42(database issue):D980-D985.
23. Purcell SM, Moran JL, Fromer M, et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature. 2014;506(7487):185-190.
24. McLarenW, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics. 2010;26(16):2069-2070.
25. Lek M, Karczewski KJ, Minikel EV, et al; Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285-291.
26. Liu X,Wu C, Li C, Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice-site SNVs. Hum Mutat. 2016;37(3):235-241.
27. Price AL, Patterson NJ, Plenge RM,Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904-909.
28. Nioi P, Sigurdsson A, Thorleifsson G, et al. Variant ASGR1 associated with a reduced risk of coronary artery disease. N Engl J Med. 2016;374 (22):2131-2141.
29. Yang J, Ferreira T, Morris AP, et al; Genetic Investigation of ANthropometric Traits (GIANT) Consortium; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat Genet. 2012;44(4):369-375, S1-S3.
30. Liu DJ, Peloso GM, Zhan X, et al. Meta-analysis of gene-level tests for rare variant association. Nat Genet. 2014;46(2):200-204.
31. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658-665.
32. Zuk O, Schaffner SF, Samocha K, et al. Searching for missing heritability: Designing rare variant association studies. Proc Natl Acad Sci U S A. 2014;111(4):E455-E464.
33. Nordestgaard BG,Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo: Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol. 1995;15(4):534-542.
34. Jensen MK, Rimm EB, Rader D, et al. S447X variant of the lipoprotein lipase gene, lipids, and risk of coronary heart disease in 3 prospective cohort studies. Am Heart J. 2009;157(2):384-390.
35. Thomsen M, Varbo A, Tybjærg-Hansen A, Nordestgaard BG. Low nonfasting triglycerides and reduced all-cause mortality: A mendelian randomization study. Clin Chem. 2014;60(5):737-746.
36. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32-41.
37. Miesenböck G, Hölzl B, Föger B, et al. Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities. J Clin Invest. 1993;91(2):448-455.